Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Melanoma 7Sarcoma 6Gliosarcoma 6Glioblastoma 6Multiple Myeloma 5Hematologic Neoplasms 5Endometrial Neoplasms 5Carcinoma, Renal Cell 5Brain Neoplasms 5Rhabdomyosarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Hodgkin Disease 4Waldenstrom Macroglobulinemia 3Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Unspecified Childhood Solid Tumor, Protocol Specific 2Unspecified Adult Solid Tumor, Protocol Specific 2Tongue Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Oligodendroglioma 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

Trastuzumab 2tipifarnib 1temsirolimus 1sapanisertib 1romidepsin 1pazopanib 1cixutumumab 1antineoplaston AS 2-1 1antineoplaston A10 1aflibercept 1Streptozocin 1Specimen Handling 1Sorafenib 1Sirolimus 1Salts 1Oxaliplatin 1Octreotide 1Nivolumab 1Magnetic Resonance Spectroscopy 1Leucovorin 1Ipilimumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunoglobulin G 1Gefitinib 1Floxuridine 1Everolimus 1Disulfides 1Cytidine Triphosphate 1Complementary Therapies 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Somatostatinoma × Sirolimus × Clear all
NCT01010126 2019-01-25

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

National Cancer Institute (NCI)

Phase 2 Completed
252 enrolled 20 charts
GastrointestinalGynecologic

Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡